Review Article
Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
Table 2
Main clinical evidences about antihyperglycemic effects of imeglimin.
| Study population | Dosage | Duration of study | Effects | Ref. |
| 33 patients with T2DM | 1500 mg/12 h | 7 days | Improved beta cell function, increased postprandial insulin release | [9] | 59 patients with T2DM | 2000 mg/day | 4 weeks | Was as effective as metformin in reducing HbA1c, has more safety and tolerability than metformin | [14] | 156 patients with T2DM | 3000 mg/day | 12 weeks | Decreased HbA1c, improved glycemic control | [16] | 170 patients with T2DM | 3000 mg/day | 12 weeks | Reduced HbA1c and FBS, showed more safety than sitagliptin monotherapy | [17] | 73 T2DM patients | 1000-3000 mg/day | 24 weeks | Improved plasma glucose control, showed good efficacy and safety especially in a dose of 2000 mg/day | [20] |
|
|